From the Journals

Oxidative stress linked to cytogenetic abnormalities in CLL


 

FROM Experimental and Molecular Pathology

Oxidative stress may play a role in pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL), according to the results of a biochemical and cytogenetic study of patients published online in Experimental and Molecular Pathology.

The study evaluated the serum levels of oxidative stress biomarkers [conjugated dienes (CD), malondialdehyde (MDA), and nitrite levels] and the levels of antioxidant biomarkers [ceruloplasmin (CP) and glutathione peroxidase (GPx)] in 64 B-CLL patients. The relationship between these biomarkers and the presence of cytogenetic abnormalities was examined, according to Tatiana Zhevak, MD, of Sechenov First Moscow (Russia) State Medical University, and colleagues.

Cytogenetic abnormalities have previously been determined to be linked to a poorer prognosis in CLL patients, and factors that increase the frequency of CA have been shown to increase the risk of rapid tumor progression, Dr. Zhevak and her colleagues stated.

Oxidative stress connection

Enhanced oxidative stress was detected in B-CLL patients as shown by their increased levels of serum CD, MDA, and nitrite, as well as a demonstrated imbalance in the antioxidant defense system as shown by an increased serum CP level and decreased serum GPx activity, according to the researchers.

In addition, these metabolic changes were found to be greater in those patients whose lymphocytes harbored specific cytogenetic abnormalities, and could be predicted by the serum levels of CD. Specifically, the odds of harboring a cytogenetic abnormality increased by a factor of 1.88 (P = .004) for every one-unit increase in serum CD level (mcmol/L), according to the authors.

“Collectively, the results support our hypothesis that oxidative stress and resulting lipid peroxidation play a role in pathogenesis of B-CLL and provide a rational basis for the use of agents regulating the pro-oxidant and antioxidant activity in the treatment of B-CLL patients,” the researchers concluded.

The research was unsponsored and the authors reported having no conflicts.

SOURCE: Zhevak T et al. Exp Mol Patholo. 2020 Oct;16:104524 doi: 10.1016/j.yexmp.2020.104524.

Recommended Reading

Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
AVAHO
Gene signature may help guide initial CLL treatment choice
AVAHO
Frontline ibrutinib saves money over chemoimmunotherapy
AVAHO
Efficacy of postvenetoclax therapy may depend on prior agent exposure in CLL
AVAHO
9/11 responders show increased risk of leukemia, other cancers
AVAHO
CAR T-cell therapy may worsen mental health in some patients
AVAHO
Novel mutations contribute to progression of venetoclax-treated CLL
AVAHO
CLL and breast cancer differ in the expression of regulatory microRNAs
AVAHO
One-third of high-risk CLL patients received treatment counter to recommendations
AVAHO
Three-drug combo promising against high-risk CLL
AVAHO